If our leaders want to make drugs more affordable for individual Americans, they need to take on PBMs — and dismantle the incentive structure that enables them to thrive at patients’ expense.
They can start by requiring PBMs to pass along the savings they negotiate to consumers at the pharmacy counter.
The Trump administration has been mum in recent weeks on its “most favored nation” drug pricing plan, which broadly aims to link U.S. prices for medicines to the lowest prices in other developed countries.
It’s unclear what those prices will be, how they’ll be determined, or how the administration will bring them about.
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.
As PBMs Drive Up Drug Prices, Silence Is Not Golden
Sally C. Pipes
If our leaders want to make drugs more affordable for individual Americans, they need to take on PBMs — and dismantle the incentive structure that enables them to thrive at patients’ expense.
They can start by requiring PBMs to pass along the savings they negotiate to consumers at the pharmacy counter.
The Trump administration has been mum in recent weeks on its “most favored nation” drug pricing plan, which broadly aims to link U.S. prices for medicines to the lowest prices in other developed countries.
It’s unclear what those prices will be, how they’ll be determined, or how the administration will bring them about.
Read the Newsmax op-ed here.
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.